Top Page
Immuron Limited
(Frankfurt:IMC)
Immuron Limited (IMC) vs. iShares MSCI Australia ETF (EWA)
Immuron Limited Business Overview & Revenue Model
Immuron Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 6.54M | 4.90M | 1.80M | 765.19K | 145.78K | 2.52M | Gross Profit |
| 4.41M | 3.34M | 1.31M | 523.50K | 94.70K | 1.83M | EBIT |
| -6.32M | -5.80M | -6.00M | -4.06M | -8.41M | -3.39M | EBITDA |
| -5.89M | -6.19M | -3.80M | -3.08M | -8.33M | -3.17M | Net Income Common Stockholders |
| -7.35M | -6.94M | -3.79M | -2.85M | -8.38M | -2.93M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 7.74M | 11.66M | 18.99M | 22.11M | 25.05M | 3.25M | Total Assets |
| 12.17M | 15.55M | 21.99M | 24.86M | 27.05M | 6.20M | Total Debt |
| 135.62K | 173.50K | 189.09K | 209.79K | 20.50K | 61.10K | Net Debt |
| -7.60M | -11.48M | -16.97M | -21.90M | -25.03M | -3.19M | Total Liabilities |
| 1.83M | 2.84M | 2.37M | 1.68M | 1.16M | 558.25K | Stockholders Equity |
| 10.34M | 12.71M | 19.62M | 23.18M | 25.90M | 5.64M |
| Cash Flow | Free Cash Flow | ||||
| -7.87M | -5.56M | -2.50M | -3.14M | -4.09M | -3.17M | Operating Cash Flow |
| -7.87M | -5.56M | -2.49M | -3.13M | -4.08M | -3.16M | Investing Cash Flow |
| 228.05K | 327.56K | -2.74M | -10.05K | -6.63K | -864.00 | Financing Cash Flow |
| -17.90K | 829.00 | -35.02K | -36.26K | 26.49M | 1.17M |
Immuron Limited Technical Analysis
Immuron Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$9.54M | 8.05 | 26.99% | ― | ― | 51.85% | |
54 Neutral | $5.37B | 3.26 | -45.10% | 3.30% | 16.81% | 0.02% | |
48 Neutral | AU$14.51M | ― | -52.70% | ― | 82.90% | -89.41% | |
46 Neutral | AU$2.68M | ― | -392.18% | ― | ― | 34.26% | |
46 Neutral | AU$12.69M | ― | -64.72% | ― | 139.19% | 33.33% | |
36 Underperform | AU$19.00M | ― | -42.50% | ― | ― | 80.96% | |
27 Underperform | AU$1.07M | ― | -147.32% | ― | ― | 26.09% |
Immuron Limited Corporate Events
Immuron Limited has issued 116,680 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, as per section 708A(5) of the Act. The company has complied with relevant provisions of the Corporations Act and confirms there is no excluded information required to be disclosed, indicating a transparent and compliant operation that may reassure stakeholders.
Immuron Limited is on track to surpass A$7 million in sales this financial year, marking a significant increase from the previous year’s A$4.9 million. The company is advancing several clinical trials, including Travelan® for traveler’s diarrhea, with results expected in October 2025, and plans to submit an IND for IMM-529 to the FDA in August 2025. Additionally, Immuron is preparing to launch ProIBS® in Australia, targeting the IBS treatment market. These developments could enhance Immuron’s market presence and strengthen its relationships with key stakeholders, including the US Department of Defense.
Immuron Limited has issued 135,800 ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company has complied with the relevant provisions of the Corporations Act and confirms there is no excluded information required to be disclosed, indicating a transparent and compliant operational stance.
Immuron Limited has announced the application for quotation of 135,800 fully paid ordinary securities on the Australian Securities Exchange (ASX), with an issue date of May 29, 2025. This move is part of previously announced transactions and may enhance the company’s market presence and liquidity, potentially impacting its operations and stakeholder interests positively.
Immuron Limited has announced a proposed issue of 135,800 fully paid ordinary securities, with the issuance date set for May 29, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s market positioning by increasing its capital base and enhancing its financial flexibility.
Immuron Limited has issued 179,664 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant provisions. This issuance reflects the company’s ongoing adherence to regulatory requirements, potentially impacting its market operations and stakeholder interests.
Immuron Limited announced the cessation of 285,741 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation may impact the company’s capital structure and could have implications for stakeholders, reflecting challenges in meeting performance conditions.
Immuron Limited has announced a new issuance of 179,664 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure and potentially improve its market position, signaling a proactive approach to leveraging financial instruments for growth.
Immuron Limited has achieved its highest sales in history, exceeding AUD$5 million in a fiscal year, driven by strong performance in both Australia and North America. The company’s Travelan® product has seen significant growth, with year-to-date sales up 46% globally compared to the previous year. This growth is attributed to strategic marketing efforts, expanded pharmacy agreements in Australia, and successful relaunch efforts in Canada. The company anticipates continued strong sales momentum through upcoming holiday periods, further solidifying its market position.